Emergent BioSolutions, Inc. appoints Niederhuber to board of directors

Emergent BioSolutions, Inc. has appointed Dr. John E. Niederhuber to the company’s board of directors as a Class III director.

Fuad El-Hibri, Emergent BioSolutions, Inc.'s chairman and CEO, said he was excited to have Niederhuber on board.

“Dr. Niederhuber is a nationally renowned surgeon and researcher who has dedicated his four-decade career to the treatment and study of cancer,” El-Hibri said. “As we expand our portfolio to include cancer therapeutics, his oncology research and clinical experience will be an invaluable asset in guiding Emergent's management team towards further growth and in increasing value for shareholders.”

Niederhuber, in return, said he looked forward to serving on Emergent BioSolutions, Inc.'s board of directors.

“I am pleased to serve on the board of a company that has a strong interest in providing new treatments to cancer patients.” Niederhuber said. “Their mission in vaccine development to protect life aligns closely with my goals to find life-saving treatments that can benefit patients worldwide.”

From 2005 to 2010, Dr. Niederhuber served as the director of the National Cancer Institute. As NCI's director, Niederhuber advanced drug and technology innovation and technology infrastructure. He also worked to bring cancer science to patients through community cancer centers and strove to reduce the inequities of cancer care.

Niederhuber recently joined Inova Health System as executive vice president and CEO of the Inova Institute for Translational Research and Personalized Medicine.

Prior to his tenure at NCI, Niederhuber was director of the University of Wisconsin Comprehensive Cancer Center and a professor of surgery and oncology at the University of Wisconsin School of Medicine.

He is a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He trained in surgery at the University of Michigan.